X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3018) 3018
Publication (211) 211
Newsletter (64) 64
Book Review (34) 34
Magazine Article (18) 18
Book Chapter (11) 11
Book / eBook (7) 7
Dissertation (2) 2
Newspaper Article (2) 2
Conference Proceeding (1) 1
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2095) 2095
carbamates - therapeutic use (1605) 1605
male (1277) 1277
animals (1044) 1044
female (1028) 1028
index medicus (948) 948
middle aged (708) 708
carbamates (676) 676
adult (642) 642
pharmacology & pharmacy (639) 639
aged (573) 573
carbamates - pharmacology (481) 481
drug therapy, combination (375) 375
carbamates - administration & dosage (372) 372
sulfonamides - therapeutic use (366) 366
rats (357) 357
carbamates - adverse effects (349) 349
treatment outcome (348) 348
mice (318) 318
piperidines - therapeutic use (313) 313
hiv infections - drug therapy (292) 292
phenylcarbamates (236) 236
dose-response relationship, drug (234) 234
benzimidazoles - therapeutic use (232) 232
rivastigmine (230) 230
cholinesterase inhibitors - therapeutic use (219) 219
toxicology (217) 217
hypoglycemic agents - therapeutic use (216) 216
clinical trials as topic (210) 210
antiviral agents - therapeutic use (201) 201
diabetes mellitus, type 2 - drug therapy (201) 201
alzheimer disease - drug therapy (196) 196
drug therapy (195) 195
hiv protease inhibitors - therapeutic use (195) 195
oncology (194) 194
administration, oral (192) 192
ritonavir - therapeutic use (181) 181
anti-hiv agents - therapeutic use (177) 177
analysis (175) 175
adolescent (174) 174
time factors (173) 173
deoxycytidine - analogs & derivatives (170) 170
carbamates - pharmacokinetics (169) 169
genotype (157) 157
neurosciences (156) 156
hepatitis c, chronic - drug therapy (150) 150
research (150) 150
capecitabine (147) 147
therapy (147) 147
drug interactions (145) 145
efficacy (145) 145
pharmacokinetics (144) 144
anthelmintics - therapeutic use (143) 143
oral fluoropyrimidine carbamate (143) 143
hepacivirus - genetics (138) 138
drug administration schedule (135) 135
carbamates - chemistry (133) 133
health aspects (132) 132
medicine, general & internal (129) 129
aged, 80 and over (128) 128
clinical neurology (128) 128
infectious diseases (128) 128
repaglinide (128) 128
double-blind (124) 124
deoxycytidine - therapeutic use (122) 122
macrocyclic compounds - therapeutic use (121) 121
sulfonamides - administration & dosage (120) 120
fluorouracil - analogs & derivatives (119) 119
care and treatment (118) 118
sulfonamides - adverse effects (114) 114
hepatitis c (112) 112
ritonavir (112) 112
drug combinations (111) 111
piperidines - pharmacology (111) 111
disease models, animal (109) 109
anilides - therapeutic use (107) 107
double-blind method (106) 106
safety (106) 106
anticonvulsants - therapeutic use (104) 104
chemistry, medicinal (104) 104
antineoplastic agents - therapeutic use (103) 103
antiviral agents (103) 103
cancer (100) 100
uracil - analogs & derivatives (100) 100
viral load (100) 100
hepatitis c virus (99) 99
medicine & public health (99) 99
psychiatry (99) 99
child (96) 96
biochemistry & molecular biology (95) 95
endocrinology & metabolism (94) 94
thiazoles - therapeutic use (94) 94
neuroprotective agents - therapeutic use (92) 92
rats, sprague-dawley (92) 92
pharmacology (90) 90
pyridines - therapeutic use (90) 90
ribavirin (90) 90
type 2 diabetes (89) 89
dosage and administration (86) 86
enzymes (86) 86
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2741) 2741
Russian (93) 93
French (64) 64
German (60) 60
Japanese (38) 38
Italian (34) 34
Spanish (22) 22
Polish (16) 16
Dutch (12) 12
Portuguese (10) 10
Czech (9) 9
Chinese (6) 6
Finnish (3) 3
Hungarian (3) 3
Slovak (3) 3
Bulgarian (1) 1
Croatian (1) 1
Norwegian (1) 1
Swedish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Liver International, ISSN 1478-3223, 01/2016, Volume 36, Issue S1, pp. 47 - 57
Journal Article
European Heart Journal, ISSN 0195-668X, 09/2015, Volume 36, Issue 34, pp. 2288 - 2296
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2014, Volume 370, Issue 17, pp. 1594 - 1603
In this trial in previously untreated patients with HCV genotype 1 infection and no cirrhosis, high rates of sustained response were achieved with three new... 
TRIAL | MEDICINE, GENERAL & INTERNAL | PLUS SOFOSBUVIR | C VIRUS-INFECTION | GENOTYPE 1 INFECTION | DACLATASVIR | SIMEPREVIR TMC435 | HEPATITIS-C | INTERFERON-FREE | TREATMENT-NAIVE PATIENTS | PHASE 2B | Anilides - therapeutic use | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Viral Load | Young Adult | Ritonavir - adverse effects | Ritonavir - therapeutic use | Adult | Female | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Uracil - therapeutic use | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Adolescent | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Drug Combinations | Uracil - analogs & derivatives | Dosage and administration | Research | Drug therapy, Combination | Hepatitis C | Drug therapy | Ribavirin | Ritonavir | Body weight | Diarrhea | Infections | Nausea | Proteinase inhibitors | Pruritus | Drug resistance | Patients | Genotype & phenotype | Cirrhosis | Sleep disorders | Hepatitis | Asthenia | Hemoglobin | Interferon | Drug dosages | Genotypes
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2014, Volume 370, Issue 17, pp. 1604 - 1614
Journal Article
Gastroenterology, ISSN 0016-5085, 2014, Volume 147, Issue 2, pp. 359 - 365.e1
Background & Aims The interferon-free regimen of ABT-450 (a protease inhibitor), ritonavir, ombitasvir (an NS5A inhibitor), dasabuvir (a non-nucleoside... 
Gastroenterology and Hepatology | IFN | PEARL-II | Ribavirin-Free | Interferon-Free Therapy | PLUS RIBAVIRIN | ABT-450/R-OMBITASVIR | VIRUS-INFECTION | TELAPREVIR | SOFOSBUVIR | CHRONIC HEPATITIS-C | COMBINATION | TRIAL | CIRRHOSIS | BOCEPREVIR | GASTROENTEROLOGY & HEPATOLOGY | Anilides - therapeutic use | Puerto Rico | Hepatitis C - drug therapy | United States | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Male | RNA, Viral - blood | Viral Load | Ritonavir - adverse effects | Time Factors | Ritonavir - therapeutic use | Adult | Female | Drug Therapy, Combination | Hepacivirus - drug effects | Antiviral Agents - therapeutic use | Europe | Ribavirin - therapeutic use | Uracil - therapeutic use | Genotype | Treatment Outcome | Macrocyclic Compounds - adverse effects | Biomarkers - blood | Macrocyclic Compounds - therapeutic use | Hepatitis C - diagnosis | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Hepacivirus - growth & development | Aged | Carbamates - therapeutic use | Uracil - analogs & derivatives | Medical colleges | Care and treatment | Proteases | Ritonavir | Biological products industry | Genetic aspects | Biological response modifiers | Hepatitis C virus | Hepatitis C | Health aspects | Ribavirin
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 7/2013, Volume 208, Issue 1, pp. 32 - 39
Background. Cobicistat (COBI) is a pharmacoenhancer with no antiretroviral activity in vitro. Methods. An international, randomized, double-blind,... 
T lymphocytes | HIV/AIDS | Antiretrovirals | Infectious diseases | RNA | HIV | Drug evaluation | AIDS | Photographs | HIV 1 | Virology | cobicistat | pharmacoenhancer | INFECTIOUS DISEASES | CO-FORMULATED ELVITEGRAVIR | RENAL-FUNCTION | INITIAL TREATMENT | MICROBIOLOGY | HIV-1-INFECTED PATIENTS | IMMUNOLOGY | DAILY LOPINAVIR/RITONAVIR | GLOMERULAR-FILTRATION-RATE | EFAVIRENZ | DOUBLE-BLIND | ONCE-DAILY DARUNAVIR/RITONAVIR | TENOFOVIR | Humans | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Thiazoles - therapeutic use | Oligopeptides - therapeutic use | Anti-HIV Agents - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Adenine - therapeutic use | Atazanavir Sulfate | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Drug Therapy, Combination | Pyridines - therapeutic use | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Double-Blind Method | Organophosphonates - therapeutic use | Ritonavir - administration & dosage | HIV-1 - drug effects | Deoxycytidine - administration & dosage | Treatment Outcome | HIV Protease Inhibitors - administration & dosage | HIV Protease Inhibitors - therapeutic use | Adenine - administration & dosage | Organophosphonates - administration & dosage | HIV Infections - drug therapy | Oligopeptides - administration & dosage | Carbamates - therapeutic use | Viral Load - drug effects | Cobicistat | Deoxycytidine - analogs & derivatives | Research | Drug therapy | HIV infection | Patient outcomes
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2014, Volume 371, Issue 25, pp. 2375 - 2382
In this study, 34 liver-transplant recipients with recurrent HCV genotype 1 infection were treated with the interferon-free regimen of ombitasvir–ABT-450/r,... 
MEDICINE, GENERAL & INTERNAL | ABT-450/R-OMBITASVIR | MULTICENTER | VIRUS-INFECTION | TELAPREVIR | THERAPY | DASABUVIR | HEPATITIS-C RECURRENCE | GRAFT | RIBAVIRIN | PEGINTERFERON-ALPHA-2B | Anilides - therapeutic use | Liver Transplantation | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Male | RNA, Viral - blood | Calcineurin Inhibitors - blood | Young Adult | Ribavirin - administration & dosage | Ritonavir - therapeutic use | Adult | Female | Drug Therapy, Combination | Hepacivirus - isolation & purification | Antiviral Agents - therapeutic use | Uracil - therapeutic use | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Sulfonamides - therapeutic use | Antiviral Agents - adverse effects | Calcineurin Inhibitors - therapeutic use | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Viral Nonstructural Proteins - antagonists & inhibitors | Uracil - analogs & derivatives | Care and treatment | Usage | Ritonavir | Liver | Dosage and administration | Transplantation | Hepatitis C | Ribavirin | Headache | Transplants & implants | Erythropoietin | Syngeneic grafts | Calcineurin | Calcineurin inhibitors | Blood transfusion | Immunosuppressive agents | Hepatitis | Allografts | Drug therapy | Genotypes | Antiviral agents | Recurrent infection | Fatigue | Proteinase inhibitors | Patients | RNA-directed RNA polymerase | Cough | Blood levels | Graft rejection | Fibrosis | Interferon | Antiviral drugs | Liver transplantation | Index Medicus | Abridged Index Medicus | Medicaments antivírics | Hepatitis C virus | Virus de l'hepatitis C | Trasplantament hepàtic | Hepatic transplantation
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2017, Volume 376, Issue 22, pp. 2134 - 2146
Journal Article
Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 04/2013, Volume 62, Issue 5, pp. 483 - 486
Journal Article
Hepatology, ISSN 0270-9139, 2008, Volume 48, Issue 6, pp. 1769 - 1778
Journal Article